Endothelin-1's chronome indicates diabetic and vascular disease chronorisk

Peptides

Volumn 18, Issue 1, 1997, Pages 119-132

  Tarquini, Brunetto ^a   Perfetto, Federico ^a   Tarquini, Roberto ^a   Cornélissen, Germaine ^b   Halberg, Franz ^b  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

atherosclerosis; chronome; chronorisk; circadian rhythm; diabetes; endothelial damage; endothelin 1; vasoconstrictor agents

Indexed keywords

CHOLESTEROL; ENDOTHELIN 1;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; BLOOD LEVEL; CHRONOLOGY; CIRCADIAN RHYTHM; CONTROLLED STUDY; DIABETES MELLITUS; ENDOTHELIUM INJURY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; RISK FACTOR; SMOKING; VASCULAR DISEASE;

EID: 0030890322     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0196-9781(96)00258-6     Document Type: Article

References (67)

1. Apfelbaum, M.; Bishop, J. S.; Cressey, D.; et al. Human or murine endocrine and metabolic rhythms after changes in meal timing with or without a fixed activity schedule. Proceedings of the 56th Meeting of the Endocrine Society, Abstract #308, 1974.
2. Artigou J. Y., Salloum J., Carayon A., et al. Variations de l'endothéline plasmatique au cours du spasme coronaire. Arch. Mal. Coeur. 86:1993;1581-1586.
3. Badimon L., Badimon J. J., Penny W., et al. Endothelium and atherosclerosis. J. Hypertens. 10:((Suppl. 1)):1992;S43-S50.
4. Bath P. M., Martin J. F. Serum platelet-derived growth factor and endothelin concentrations in human hypercholesterolemia. J. Int. Med. 230:1991;313-317.
5. Bingham C., Arbogast B., Cornélissen Guillaume G., et al. Inferential statistical methods for estimating and comparing cosinor parameters. Chronobiologia. 9:1982;397-439.
6. Botting R., Vane J. R. Vasoactive mediators derived from the endothelium. Arch. Mal. Coeur Vaiss. 4:1989;11-14.
7. Cairns H. S., Rogerson M., Fairbanks L. D., et al. Endothelin and cyclosporin nephrotoxicity [letter]. Lancet. 157:1988;977.
8. Chester A. H., O Neil G. S., Allen S. P., et al. Effect of endothelin on normal and diseased human coronary arteries. Eur. J. Clin. Invest. 22:1991;210-213.
9. Cody R., Haas G., Binkley P., et al. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation. 85:1992;504-509.
10. Collier A., Leach J. P., McLellan A., et al. Plasma endothelin-like immunoreactivity levels in IDDM patients with microalbuminuria. Diabetes Care. 15:1992;1038-1040.
11. Cornélissen G., Breus T. K., Bingham C., et al. Beyond circadian chronorisk: Worldwide circaseptan-circasemiseptan patterns of myocardial infarctions, other vascular events, and emergencies. Chronobiologia. 20:1993;87-115.
12. Cornélissen G., Halberg F. Broadly pertinent chronobiology methods quantify phosphate dynamics (chronome) in blood and urine. Clin. Chem. 38:1992;329-333.
13. Cornélissen, G.; Halberg, F. Introduction to chronobiology. Medtronic chronobiology Seminar #7, Minneapolis: Medtronic, April 1994:52. Available free of charge while supplies last from Patrick Delmore, Director of Communications, Medtronic Inc., 7000 Central Ave. N.E., Minneapolis, MN 55432, USA.
14. Dekker G. A., Kraayenbrink A. A., Zeeman G. G., van Kamp G. J. Increased plasma levels of the novel vasoconstrictor peptide endothelin in severe preeclampsia. Eur. J. Obstet. Gynecol. Reprod. Biol. 40:1991;215-220.
15. Dubin D., Pratt R. E., Cooke J. P., Dzau V. J. Endothelin, a potent vasoconstrictor, is a vascular smooth muscle mitogen. J. Vasc. Med. Biol. 1:1989;150-154.
16. Günther R., Herold M., Halberg E., Halberg F. Circadian placebo and ACTH effects on urinary cortisol in arthritics. Peptides. 1:1980;387-390.
17. Haak T., Jungmann E., Felber A., et al. Increased plasma levels of endothelin in diabetic patients with hypertension. Am. J. Hypertens. 5:1992;161-166.
18. Halberg F. Changes in eosinophil count of mice with venisections repeated at intervals of several days. Proc. Soc. Exp. Biol. 82:1953;160-162.
19. Halberg F. Chronobiology. Annu. Rev. Physiol. 31:1969;675-725.
20. Halberg F. Chronobiology: Methodological problems. Acta Med. Rom. 18:1980;399-440.
21. Halberg F., Carandente F., Cornélissen G., Katinas G. S. Glossary of chronobiology. Chronobiologia. 4:((Suppl. 1)):1977;189.
22. Halberg F., Cornélissen G., Carandente F. Chronobiology leads toward preventive health care for all: Cost reduction with quality improvement. A challenge to education and technology via chronobiology. Chronobiologia. 18:1991;187-193.
23. Halberg F., Cornélissen G., Halberg E., et al. Chronobiology of human blood pressure. Medtronic Continuing Medical Education Seminars. 4th ed. 1988;242.
24. Halberg F., Halberg E., Carandente F. Chronobiology and metabolism in the broader context of timely intervention and timed treatment. Diabetes Research Today, Meeting of the Minkowski Prize Winners, Symposia Medica Hoechst 12 (Capri). 1976;45-95 F. K. Schattauer Verlag, Stuttgart.
25. Halberg F., Tong Y. L., Johnson E. A. Circadian system phase - an aspect of temporal morphology; procedures and illustrative examples. Proc. International Congress of Anatomists. Mayersbach H. v. The cellular aspects of biorhythms, symposium on biorhythms. 1967;20-48 Springer-Verlag, Berlin.
26. Halberg F., Visscher M. B. Regular diurnal physiological variation in eosinophil levels in five stocks of mice. Proc. Soc. Exp. Biol. 75:1950;846-847.
27. Hattori Y., Kasai K., Nakamura T., et al. Effect of glucose and insulin on immunoreactive endothelin-1 release from cultured porcine aortic endothelian cells. Metabolism. 40:1991;165-169.
28. Hladovec J. The role of endothelium in the pathogenesis of vascular diseases. Cor Vasa. 31:1989;433-443.
29. Hu R-M., Levin E. R., Pedram A., Frank H. J. L. Insulin stimulates the production and secretion of endothelin from bovine endothelial cells. Diabetes. 42:1993;351-358.
30. Inoue A., Yanagisawa M., Kimura S., et al. The human endothelin family: Three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc. Natl. Acad. Sci. USA. 86:1989;2863-2867.
31. Inoue A., Yanagisawa M., Takuya Y., et al. The human prepro-endothelin-1 gene. J. Biol. Chem. 264:1990;14954-14959.
32. Koller J., Mair P., Wieser C., et al. Endothelin and big endothelin concentrations in injured patients. N. Engl. J. Med. 325:1991;1518.
33. Komatsumoto S., Nara M. Changes in the level of endothelin-1 with aging. Jpn. J. Geriatr. 32:1995;664-669.
34. Lerman A., Edwards B. S., Hallett J. W., et al. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N. Engl. J. Med. 325:1991;997-1001.
35. Lerman A., Kubo S. H., Tschumperlin L. K., Burnett J. C. Jr. Plasma endothelin concentrations in humans with end-stage heart failure and after heart transplantation. J. Am. Coll. Cardiol. 20:1992;849-853.
36. Licata G., Scaglione R., Avellone G., et al. Obesity, hypertension and atherosclerosis. Int. Angiol. 12:1993;326-330.
37. Lüscher T. F. Possibilities and perspectives of pharmacotherapy for endothelial protection. Curr. Opin. Nephrol. Hypertens. 2:1993;129-136.
38. Lüscher T. F., Oemar B. S., Boulanger C. M., Hahn A. W. A. Molecular and cellular biology of endothelin and its receptors. Part I. J. Hypertens. 11:1993;7-11.
39. Lüscher T. F., Tanner F. C., Tschudi M. R., Noll G. Endothelial dysfunction in coronary artery disease. Annu. Rev. Med. 44:1993;395-418.
40. Miyauchi T., Yanagisawa M., Iida K., et al. Age- and sex-related variation of plasma endothelin-1 concentration in normal and hypertensive subjects. Am. Heart J. 123:1992;1092-1093.
41. Morise T., Takeuchi Y., Kawano M., et al. Increased plasma levels of immunoreactive endothelin and von Willebrand factor in NIDDM patients. Diabetes Care. 18:1995;87-89.
42. Naruse M., Kawana M., Hifumi S., et al. Plasma immunoreactive endothelin, but not thrombomodulin, is increased in patients with essential hypertension and ischemic heart disease. J. Cardiovasc. Pharmacol. 17:((Suppl. 7)):1991;S471-S474.
43. Neild G. H. Endothelin plasma levels in hypertensive patients with vascular disease. J. of Hypertens. Suppl. 12:1994;S17-S20.
44. Omland T., Bonarjee V. V., Lie R. T., Caidahl K. Neurohumoral measurements as indicators of long-term prognosis after acute myocardial infarction. Am. J. Cardiol. 76:1995;230-235.
45. Patino R., Ibarra J., Molino A., et al. Increased plasma endothelin in diabetes: An atherosclerosis marker? Diabetologia. 37:1994;333-334.
46. Perfetto F., Tarquini R., Piluso A., et al. Sex difference, age and circadian rhythmometry of circulating endothelin-1. Biol. Rhythm Res. 26:1995;432.
47. Reinberg A., Gervais P., Halberg F., et al. Mortalité des adultes: Rythmes circadiens et circannuels dans un hôpital parisien et en France. Nouv. Presse Med. 2:1973;289-294.
48. Schrader J., Tebbe U., Borries M., et al. Plasma endothelin in normal probands and patients with nephrologic-rheumatologic and cardiovascular diseases. Klin. Wochenschr. 68:1990;774-779.
49. Simonson M. S., Dunn M. J. The molecular mechanisms of cardiovascular and renal regulation by endothelin peptides. J. Lab. Clin. Med. 119:1992;622-639.
50. Simpson H. W., Bartter F. C., Halberg F., et al. A circaoctohoran rhythm of urine epinephrine excretion in man. Prog. Clin. Biol. Res. 341A:1990;157-160.
51. Smolensky M., Halberg F., Sargent F. II. Chronobiology of the life sequence. Itoh S., Ogata K., Yoshimura H. Advances in climatic physiology. 1972;281-318 Igaku Shoin Ltd, Tokyo.
52. Sokal R. R., Rohlf F. J. Biometry: The principles and practice of statistics in biological research. 2nd ed. 1981;Freeman & Co, San Francisco.
53. Tarquini B. Semeiotica Medica: Lineamenti attuali e note di diagnostica. 2:1983;Societá Editrice Esculapio, Bologna.
54. Tarquini B., Benvenuti M., Moretti R., et al. Atherosclerotic chronorisk, recognized by autorhythmometry combined with hemopsies as a step toward chronophylaxis. Chronobiologia. 6:1979;162-163.
55. Tarquini B., Borghi G., Galli F., et al. Biological noise and clinical laboratory: hints of pathophysiology. Fanfani M., Tarquini B. Reference values & chronobiology, XV World Congress of Anatomic and Clinical Pathology, Florence, May 16-20, 1989. 1989;73-85 Nuova Grafica Fiorentina, Florence.
56. Tarquini B., Gheri R., Romano S., et al. Circadian mesor-hyperprolactinemia in fibrocystic mastopathy. Am. J. Med. 66:1979;229-237.
57. Taylor R. N., Varma M., Teng N. N., Roberts J. M. Women with preeclampsia have higher plasma endothelin levels than women with normal pregnancies. J. Clin. Endocrinol. Metab. 71:1990;1675-1677.
58. Tomita K., Kazutomo U., Nakanishi T., et al. Plasma endothelin levels in patients with acute renal failure. N. Engl. J. Med. 321:1989;1127.
59. Vanhoutte P. M. Is endothelin involved in the pathogenesis of hypertension? Hypertension. 21:1993;747-751.
60. Vincent M. B., Bakken I. J., White L. R. Endothelin-1 inhibits the vasodilation induced by substance P in isolated porcine ophthalmic artery. Funct. Neurol. 7:1992;475-480.
61. Weber K. T., Anversa P., Armstrong P. W., et al. Remodeling and reparation of the cardiovascular system. J. Am. Coll. Cardiol. 20:1992;3-16.
62. Wieczorek I., Haynes W. G., Webb D. J., et al. Raised plasma endothelin in unstable angina and nonQ-wave myocardial infarction: Relation to cardiovascular outcome. Br. Heart J. 72:1994;436-441.
63. Wolpert H. A., Steen S. N., Istfan N. W., Simonson D. C. Insulin modulates circulating endothelin-1 levels in humans. Metabolism. 42:1993;1027-1030.
64. Yanagisawa M., Kurihara H., Kimura S., et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 332:1988;411-415.
65. Yasuda M., Kohono M., Tahara A., et al. Circulating immunoreactive endothelin in ischemic heart disease. Am. Heart J. 119:1990;801-806.
66. Yoshibayashi M., Nishioka K., Nakao K., et al. Plasma endothelin levels in healthy children: High values in early infancy. J. Cardiovasc. Pharmacol. 17:((Suppl. 7)):1991;S404-S405.
67. Ziv I., Fleminger G., Djaldetti R., et al. Increased plasma endothelin-1 in acute ischemic stroke. Stroke. 23:1992;1014-1016.